CN103417591B - A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof - Google Patents
A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof Download PDFInfo
- Publication number
- CN103417591B CN103417591B CN201210163730.4A CN201210163730A CN103417591B CN 103417591 B CN103417591 B CN 103417591B CN 201210163730 A CN201210163730 A CN 201210163730A CN 103417591 B CN103417591 B CN 103417591B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- weight portion
- radix
- apoplexy
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine composition for the treatment of apoplexy and preparation method thereof, it contains Radix Notoginseng, Radix Et Caulis Acanthopanacis Senticosi, Rhizoma Chuanxiong etc., and this pharmaceutical composition prescription is simply effective.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of apoplexy and preparation method thereof.
Background technology
Apoplexy (Stroke) is the formal name used at school of apoplexy, it is a kind of cerebral blood circulation obstacle disease of unexpected onset, be cerebrovas-cularaccident again, refer to the patient at cerebrovascular disease, because various risk factor causes internal artery narrow, inaccessible or break, and cause acute brain disturbance of blood circulation, clinical signs is the sings and symptoms of transient or permanent disordered brain function.Apoplexy is the common refractory disease of serious harm human health and life security, first of four large difficult disease that motherland's medical science is classified as " wind, consumptive disease, distension, diaphragm ", there is obvious three-hypers (sickness rate is high, disability rate is high, mortality rate high) phenomenon.2,000,000 are reached according to the annual patient with cerebral apoplexy that occurs of statistics China.Sickness rate is up to 1,20/,100,000.Now survival stroke patient 7,000,000, wherein 4,500,000 patients disability and can't take care of oneself in various degree.Disability rate is up to 75%.The annual stroke patient dead 1,200,000 of China.Must cross the patient of apoplexy, also easily recur again, often recur once, increase the weight of once.Apoplexy causes great threat to human health and life, brings considerable distress to patient, and family and society bring heavy burden.
Hypertension, diabetes, heart disease, metabolism disorder of blood lipid, transient ischemic attack, smoking and excessive drinking, hemorheology are disorderly and fat etc. may be all the risk factor of apoplexy, the symptom at apoplexy initial stage is dizziness, numb limbs and tense tendons, temporary pronounce indistinctly or talk ineffective, limb adynamia or movable ineffective, to fall suddenly from headaches different at ordinary times, unknown cause or to fall in a swoon etc., have a strong impact on orthobiosis.Apoplexy is divided into ischemic (transient ischemic attack, Atherosclerosis and thrombosis and cerebral infarction, lacunar infarction, cerebral embolism) and the large class of hemorrhagic (cerebral hemorrhage, subarachnoid hemorrhage) two, cause ischemia apoplexy also known as cerebral infarction by angiemphraxis, account for the 70%-80% of apoplexy.In cerebrovascular sudden death event, cerebral infarction accounts for 80%, suddenly cerebral infarction occurs, can make patient lethal, disable.Cerebral infarction refers to that the cerebral tissue local feeding artery blood perfusion occurred suddenly reduces or blood flow interrupts completely, stops blood supply, oxygen supply, for sugar etc., this local brain tissue disintegrate is destroyed.The main cause of cerebral infarction is 1. thromboembolism caused by atherosclerosis; 2. heart source embolus caused by cerebral embolism; 3. vasculitis, blood vessel injury and the wound etc. that cause of a variety of causes.Cerebral infarction is generally fallen ill in nighttime sleep, and Chang Weici WA in morning finds limb adynamia or hemiplegia, and how unconscious obstacle, blood pressure can be normal or higher, can have arteriosclerosis history.Cerebral infarction accounts for 60% ~ 70% of cerebral apoplexy patient sum, mainly comprises cerebral thrombosis and cerebral embolism.The former make the narrow or obturation of arterial lumen cause cerebral tissue local intra-arterial blood perfusion to reduce due to the atherosis and thrombosis in cerebral arteries system or local brain tissue caused by stopping downright bad.
Rhizoma Chuanxiong record in the Pharmacopoeia of the People's Republic of China (version in 2010 ".Rhizoma Chuanxiong is a kind of Chinese medicine, has activating blood circulation to dissipate blood stasis, a medicinal efficacy of analgesic therapy of regulating the flow of vital energy.Theory of Chinese medical science payes attention to the normal operation of gas, blood, body fluid, thinks that the stagnation of QI is not all right, has blood stasis.Cerebral ischemia is exactly due to qi stagnation blood stasis, and blood vessels are obstructed, thus causes nervous system dysfunction.Rhizoma Chuanxiong is " in blood gas medicine ", and the thin gas of taste is male, and property circulates most, and pungent faling apart walks to alter effect very by force, and can rise and can fall apart, the rising head, side reaches extremity, the descending sea of blood, has effect of activating blood circulation to dissipate blood stasis, circulation of qi promoting analgesic therapy, cures mainly apoplexy and enters brain headache, the diseases such as hemiplegia.Domestic large quantity research is carried out to Rhizoma Chuanxiong function of promoting blood circulation to disperse blood clots and mechanism; confirm that Rhizoma Chuanxiong can improve brain and Peripheral Microcirculation, obviously increase cerebral blood flow, can platelet activation be suppressed; reduce erythrocyte and Platelet, to experimental cerebral ischemia tectology and brain function, there is protective effect.
Radix Et Caulis Acanthopanacis Senticosi is recorded in the Pharmacopoeia of the People's Republic of China equally.Modern medicine research proves that the action character of Radix Et Caulis Acanthopanacis Senticosi is substantially identical with Radix Ginseng, has and regulates body disorderly, make it to be tending towards normal function.Have good antifatigue effect, comparatively Radix Ginseng is remarkable, and significantly can improve hypoxia-bearing capability.The function such as invigorating middle warmer, benefit essence, strong will, wind-damp dispelling, strengthening bone and muscle, blood circulation and promoting silt, stomach invigorating diuresis.Clothes of a specified duration " are made light of one's life by commiting suicide and are endured hardships ".Radix Et Caulis Acanthopanacis Senticosi contains noticeable composition---and eleutheroside, it can stimulate mind & body vigor.Numerous scientific publications about Radix Et Caulis Acanthopanacis Senticosi demonstrates its antifatigue effect, strengthens endurance and ability, increases alert and resourceful and learning capacity.Numerous usage obtains confirmation all in human experimentation.Radix Et Caulis Acanthopanacis Senticosi is rehabilitation after being ill, bears too much pressure or anxiety, works excessive, chronic disease cause weakly crowd and those need to reach very welcome self-medication medicine in the people on physiology and psychological performance peak.It has support immune system to have the report of considerable quantity to point out equally at present, recovers improper hypotension, improves blood circulation, makes disorderly glycolipid metabolism normalization, liver, testis, anabolic effect of bone density and other vitals.Simultaneously Chinese patent ZL94107718.7 discloses Radix Et Caulis Acanthopanacis Senticosi injection and is used for the treatment of the cardiovascular disease such as cerebral infarction, coronary heart disease.
Radix Notoginseng comes from Compendium of Material Medica: release famous mountain paint, Radix Stephaniae Sinicae (Radix Stephaniae Dielsianae).Ancient times is also known as clear ginseng, Herba Wedeliae Wallichii, Panax pseudoginseng, Typhonium flagelliforme (Lodd.) Blume, Radix Notoginseng.Radix Notoginseng has dissipating blood stasis hemostasis, effect of subduing swelling and relieving pain.Cure mainly spitting of blood, spit blood, epistaxis, has blood in stool, metrorrhagia, traumatic hemorrhage, and breast ventral spine pain, tumbling down swells and ache.Compendium of Material Medica cloud: " pseudo-ginseng hemostatic, loose blood, analgesic therapy." " beautiful Chinese catalpa medicine solution " cloud: " Radix Notoginseng and battalion's hemostasis, clots absorbing of promoting blood circulation, clots absorbing blood and hold back fresh blood.”
But have no in prior art by Rhizoma Chuanxiong, Radix Notoginseng and Radix Et Caulis Acanthopanacis Senticosi with the use for the treatment of apoplexy.
Summary of the invention
The invention provides a kind of pharmaceutical composition for the treatment of apoplexy newly, this prescription is simply effective, for patients with cerebral apoplexy provides a kind of new medication to select.
The invention provides a kind of pharmaceutical composition for the treatment of apoplexy, containing the crude drug with following weight proportion in this pharmaceutical composition: Rhizoma Chuanxiong 5-40 weight portion, Radix Et Caulis Acanthopanacis Senticosi 9-40 weight portion, Radix Notoginseng 2-15 weight portion.
The preferred crude drug containing having following weight proportion further in described pharmaceutical composition: Rhizoma Chuanxiong 13-30 weight portion, Radix Et Caulis Acanthopanacis Senticosi 27-35 weight portion, Radix Notoginseng 3-9 weight portion.
The further preferred crude drug containing having following weight proportion in described pharmaceutical composition: Rhizoma Chuanxiong 15-20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30-35 weight portion, Radix Notoginseng 3-4 weight portion.
Pharmaceutical composition of the present invention most preferably one of prescription is the crude drug containing having following weight proportion: Rhizoma Chuanxiong 15 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion.
Pharmaceutical composition of the present invention most preferably one of prescription is the crude drug containing having following weight proportion: Rhizoma Chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion.
In aforementioned pharmaceutical compositions, Rhizoma Chuanxiong can be replaced by one of in Ligusticum slnense, western rhizome of chuanxiong, golden rhizome of chuanxiong or eastern rhizome of chuanxiong.
In aforementioned pharmaceutical compositions, Radix Et Caulis Acanthopanacis Senticosi can be replaced by Cortex Acanthopancis.
In aforementioned pharmaceutical compositions, Radix Notoginseng can be replaced by Folium Notoginseng, flower of Radix Notoginseng or Pollen Typhae.
Apoplexy in the present invention is preferably cerebral infarction, is more preferably cerebral infarction.
Pharmaceutical composition of the present invention and pharmaceutically acceptable carrier can be made following dosage form and comprise injection, oral liquid, syrup, tablet, pill, capsule, suppository, powder, Emulsion, suspension or granule etc. together with excipient.
The present invention still further provides a kind of method preparing described pharmaceutical composition, and it adds Radix Notoginseng powder in filtrate, dry pharmaceutical composition after stirring and evenly mixing after comprising the steps: that Rhizoma Chuanxiong and Radix Et Caulis Acanthopanacis Senticosi mixing decoct.
Pharmaceutical composition of the present invention adopts line brush to block middle cerebral artery and causes focal cerebral ischemia in rats damage model, observe pharmaceutical composition of the present invention and can effectively reduce rat brain tissue water content, cerebral infarction volume, and effectively improve rat behavioristics etc.Test proof, in pharmaceutical composition of the present invention, three taste crude drug compatibilities use, and obviously can play synergistic function simultaneously, and drug effect is clear and definite, quality controllable, provide a kind of new selection for the treatment of apoplexy medicine for clinical.And know through a large amount of clinical experimental study, this pharmaceutical composition can embody its significant curative effect on the person.
Simultaneously pharmaceutical composition of the present invention, its prescription meets theory of Chinese medical science, and be monarch drug with Rhizoma Chuanxiong in side, the pungent temperature of Rhizoma Chuanxiong is walked to alter and circulation of qi promoting, and be the gas medicine in blood, have the up head, middle relieving stagnation, effect of the descending sea of blood, the treasure in the side's of being medicine, effect is the best.Radix Et Caulis Acanthopanacis Senticosi, replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization, bone and muscle strengthening.Radix Et Caulis Acanthopanacis Senticosi can promote ribonucleic acid, the synthesis of protein, improves human body SOD and scavenging activated oxygen, thus has protective effect to brain cell and neurocyte.Radix Notoginseng function is enriched blood, and blood stasis removing damages, hemostasis nosebleed, and can lead to and can mend, have hemostasis not stay blood stasis, new advantage is not hindered in promoting the circulation of blood; Supplementary Amplifications of the Compendium of Materia Medica is said " ginseng qi-tonifying the first, Radix Notoginseng enriches blood the first, taste with and merit also etc., therefore have the laudatory title of Panax pseudoginseng ".The blood vessel dilating of Radix Notoginseng, the effect reducing blood pressure, improve microcirculation, increase blood flow, can prevention and therapy heart and brain tissues ischemia, anoxia effectively, and defying age, strengthens learning and memory ability; Take a broad view of full side, blood stasis dispelling and do not stay the stasis of blood, make the stasis of blood go new life, QI and blood passes unimpeded, and effectively treats the caused persistent ailment of cerebral infarction for residence tonification and dredging.
Detailed description of the invention
Following embodiment; only can be interpreted as it is further illustrating content of the present invention; but the further restriction that should not be construed scope; all based on protection content of the present invention; according to ordinary skill and the usual means of those skilled in the art; under the prerequisite not departing from basic thought of the present invention, the amendment of other various ways made, replacement and change all should belong to protection scope of the present invention.
The preparation of embodiment one pharmaceutical composition C4
Rhizoma Chuanxiong 4kg and Radix Et Caulis Acanthopanacis Senticosi 6kg adds 10 times amount water soaking 1h, heating extraction twice, each 1h after mixing, extractum liquid is condensed into after merging filtrate, in extractum liquid, added the Radix Notoginseng fine powder 600g of 100 mesh sieves, in 60 DEG C of oven dryings after stirring and evenly mixing, obtain dry extract and be about 1.56kg.Extract powder is sealed, preserves in 0 ~ 4 DEG C of refrigerator.
The preparation of embodiment two pharmaceutical composition
Table 1 Chinese medicine compositions is according to the weight portion of crude drug, and according to the preparation method of embodiment one, wherein raw medicinal herbs equal proportion used is amplified, and prepares corresponding pharmaceutical composition.
The weight portion of the crude drug of table 1 pharmaceutical composition
| Group | Rhizoma Chuanxiong (weight portion) | Radix Et Caulis Acanthopanacis Senticosi (weight portion) | Radix Notoginseng (weight portion) |
| A | 0 | 30 | 3 |
| B | 20 | 0 | 0 |
| C1 | 40 | 9 | 15 |
| C2 | 30 | 27 | 9 |
| C3 | 18 | 35 | 4 |
| C4 | 20 | 30 | 3 |
| C5 | 15 | 30 | 3 |
| C6 | 13 | 27 | 3 |
| C7 | 10 | 15 | 6 |
| C8 | 5 | 40 | 2 |
According to following ratio and formula, use the Rhizoma Chuanxiong in Ligusticum slnense, western rhizome of chuanxiong, golden rhizome of chuanxiong or eastern rhizome of chuanxiong alternative embodiment one respectively, with Radix Et Caulis Acanthopanacis Senticosi in Cortex Acanthopancis or Folium Acanthopanacis Senticosi alternative embodiment one, with the Radix Notoginseng that Pollen Typhae, Folium Notoginseng or flower of Radix Notoginseng alternative embodiment are a kind of, prepare corresponding pharmaceutical composition respectively.Wherein the weight portion of concrete crude drug is composed as follows:
C9 group: the weight proportion of medical material component is respectively Ligusticum slnense 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion
C10 group: the weight proportion of medical material component is respectively western rhizome of chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion
C11 group: the weight proportion of medical material component is respectively golden rhizome of chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion
C12 group: the weight proportion of medical material component is respectively eastern rhizome of chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion
C13 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portion, Cortex Acanthopancis 30 weight portion, Radix Notoginseng 3 weight portion
C14 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Pollen Typhae 3 weight portion
C15 group: the weight proportion of medical material component is respectively Ligusticum slnense 20 weight portion, Cortex Acanthopancis 30 weight portion, Pollen Typhae 3 weight portion
C16 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Folium Notoginseng 3 weight portion
C17 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, flower of Radix Notoginseng 3 weight portion
C18 group: the weight proportion of medical material component is respectively Rhizoma Chuanxiong 20 weight portion, Folium Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion
Embodiment three medicine is on the impact of rat behavioristics, cerebral tissue water content and infarction of brain volume
1.1 test material
Experimental animal: SD rat, Quan Xiong, SPF level, body weight 250 ~ 320g, is provided by Sichuan Academy of Medical Sciences, production licence number: SCXK(river) 2008-24.
1.2 test reagent
Paraformaldehyde (Paraformaldehyde): Chengdu Ke Long chemical reagent factory, lot number: 20060602.
Sodium dihydrogen phosphate: Chengdu Ke Long chemical reagent factory, lot number: 20091112.
Sodium hydrogen phosphate: Chengdu Ke Long chemical reagent factory, lot number: 20080916.
Sodium hydroxide: Chengdu Ke Long chemical reagent factory, lot number: 20091103.
Red tetrazolium (Redtetrazolium, TTC): Shanghai Ling Jin Fine Chemical Co., Ltd, lot number: 20080501.
Chloral hydrate: Chengdu Ke Long chemical reagent factory, lot number: 20070101.
Nimodipine tablet: Jingxi district, Shaanxi pharmaceutcal corporation, Ltd, lot number: H61022174.
The process of pharmaceutical composition A, B, C4: the extract powder taking respective amount adds water after adding the grinding of micro-POLYSORBATE 80 and is made into suspension.
1.3 line brush block middle cerebral artery and cause the preparation of focal cerebral ischemia in rats damage model
Rats by intraperitoneal injection 10% chloral hydrate 3.0 ~ 3.3ml/kg anaesthetizes, dorsal position is fixed, neck median line about 2mm to the right otch is about 4cm, with the lymphoid tissue of mosquito forceps blunt separation under it and body of gland, by ophthalmology straight forceps and curved tweezer separating muscle fascia and right carotid (CCA), in nearly crotch coiling, continue to be separated external carotid artery (ECA) and internal carotid artery (ICA), in crotch ligation ECA.Along ICA toward interior about 4mm place careful separation arteria pterygopalatina, and ligation; The nearly crotch of ICA is for line; Cut an osculum with eye scissors, self-control hordeolum auxiliary under fishing line (diameter 0.26mm) is inserted into ICA, send into about 20mm to have sense of conflicting for degree, namely realize the blocking-up (MCAO) to middle cerebral artery.Fasten the standby line of ICA and CCA distal end with static line bolt.Drip appropriate gentamycin dilute solution, layer-by-layer suture otch is also sterilized.Keep anus temperature 37 ± 0.5 DEG C in art, postoperative insulation is regained consciousness to animal.
1.4 medicines are on the impact of rat behavioristics, cerebral tissue water content and infarction of brain volume
Get healthy male rat, body weight 250 ~ 320g, is divided into sham operated rats at random, model control group, positive drug nimodipine group, test medicine A, B, C4 group, each test medicine group administration 650mg/Kg(650mg is extract powder amount), the administration of positive drug group is 10mg/Kg.Each group of administration is every day 1 time, and continuous gastric infusion 21 days, in modeling as stated above (sham operated rats is only separated common carotid artery) in the 14th day, in the 21st day laggard line correlation index test of last administration 1h.
1.4.1 the ethological scoring of rat measures
Standards of grading with reference to " pharmacological experimental methodology " [Xu Shuyun, Bian Rulian, Chen Xiu, pharmacological experimental methodology, Beijing: People's Health Publisher, 2001,1067] are carried out:
1. Mus tail observes forelimb flexing situation, as two forelimb symmetry stretches to ground, is designated as 0 point, and the offside forelimb as operation occurs that wrist is bent, elbow flexing, shoulder inward turning or existing wrist elbow flexing have again shoulder inward turning person, counts 1,2,3,4 point respectively.
2. animal is placed in ground grading, pushes away both shoulders respectively and move to bilateral, check resistance, as strong in bilateral resistance equity, count 0 point, resistance descender during as promoted to the offside of operation, be divided into gently according to decline degree difference, in, weigh three degree, count 1,2,3 point respectively.
3. two for animal forelimb is put on a wire netting, observe the muscular tension of two forelimb.The muscular tension of two forelimb is reciprocity and strong person counts 0 point, counts 1,2,3 point equally according to operation offside limb tension force decline degree difference.
4. animal has and does not stop, to the side person of turn-taking, to count 1 point.
According to standards of grading, full marks are 11 points, and mark is higher, and the delayed ischemic neurological deficits of animal is more serious, and experimental result is in table 2.
Table 2 medicine is to focal cerebral ischemia in rats injured nerve neurological deficit score
Compare with model control group: * P<0.05, * * P<0.01
Table 2 result shows, and compare with model control group, each administration group Neurological deficits value all has reduction in various degree, and its Chinese medicine C4 group reduces comparatively obvious, and its difference has the statistical significance (P<0.01) of highly significant.
1.4.2 the mensuration of cerebral tissue water content
Rat sacrificed by decapitation, remove rhinencephalon, brain stem, cerebellum, get brain part, be placed in weighing botle, labelling also claims weight in wet base, then puts into thermostatic drying chamber and dries to constant weight (namely twice weight difference is less than 1%) in 60 DEG C, takes out and claims its dry weight, by the water content of following formulae discovery cerebral tissue, experimental result is in table 3:
Table 3 medicine is to focal cerebral ischemia in rats injured brain tissue water content
Compare with model control group: * P<0.05, * * P<0.01
Table 3 result shows, and each administration group all has improvement in various degree to the cerebral tissue weight in wet base of rat infarction, water content, and its Chinese medicine C4 group is improved comparatively obviously, and its difference has the statistical significance (P<0.01) of highly significant.
1.4.3 the mensuration of infarction of brain volume
Rapid taking-up brain, quick-freezing about 15min in-20 DEG C of refrigerators, get coronalplane and be evenly cut into the thick brain sheet of 2mm, put into rapidly 2%TTC solution, 30min is hatched in 37 DEG C of lucifuges, stir once every 7 ~ 8min therebetween, brain sheet is made to touch dye liquor equably, after dyeing, normal brain activity sheet is rose, and infarction tissue presents white, boundary line is comparatively clearly demarcated, the brain sheet of having hatched is taken out, digital camera is taken pictures, input computer, its infarct size is calculated with computer aided video system, each brain sheet Infarction volume (equal infarct size and be multiplied by 2mm) sum is total Infarction volume.Calculate the ratio of total Infarction volume and brain cumulative volume.Experimental result is in table 4:
Table 4 medicine damages cerebral infarction volume to focal cerebral ischemia in rats
Compare with model control group: * P<0.05, * * P<0.01
Experimental result shows, each administration group cerebral tissue Infarction volume all has minimizing in various degree, and its Chinese medicine C4 group reduces comparatively obvious, and its difference has the statistical significance (P<0.01) of highly significant.
Embodiment three different pharmaceutical group is on the impact of rat behavioristics, cerebral tissue water content and infarction of brain volume
Experiment material, reagent and model construction are with embodiment two.
Get healthy male rat, body weight 250 ~ 320g, be divided into sham operated rats immediately, model control group, positive drug nimodipine group, test medicine C1-C18 group, administering mode: each test medicine group administration 650mg/Kg(650mg is extract powder amount), the administration of positive drug group is 10mg/Kg, each group of administration is every day 1 time, continuous gastric infusion 21 days, in modeling as stated above (sham operated rats is only separated common carotid artery) in the 14th day, modeling the 5th day, within 7 days, carry out the ethological scoring of rat with method, cerebral infarction volume is carried out with method after (i.e. modeling the 7th day) last administration 1h in the 21st day, brain water content index test, testing result is in table 5, 6.
1, the ethological scoring of rat measures
The shadow of different time points Neurological deficits after table 5 pair focal cerebral ischemia in rats modeling
Compare with model control group: * P<0.05, * * P<0.01
Experimental result shows, and compares with model control group, and each administration group the 5th day, 7 days Neurological deficits values after modeling all have reduction (P<0.01 ~ 0.05) in various degree.
2, to the mensuration of Rats after Focal Cerebral Ischemia cerebral infarction volume and water content
Table 6 pair Rats after Focal Cerebral Ischemia cerebral infarction volume and water content
Compare with model control group: * P<0.05, * * P<0.01
Experimental result show, compare with model control group, each administration group to rat cerebral infarction volume when brain water content all have improvement result (P<0.01 ~ 0.05) in various degree.
Embodiment four clinical and experimental study
(1) inclusive criteria
1. cerebral CT or brain MRI show clear and definite infarction responsibility lesions.
2. clear and definite nervous system defect location sign is had.
3. nervous system other diseases is got rid of.
(2) exclusion standard
1. CT shows the patient of clear and definite stigma.
2. cerebral embolism and taking the patient of other anticoagulants.
3. be in a bad way and there is eating difficulties.
4. infarction is caused by cerebrovascular malformation repeatedly.
(3) divide into groups: two groups are divided at random respectively to the patient meeting inclusive criteria:
1. Rhizoma Chuanxiong 15g, Radix Et Caulis Acanthopanacis Senticosi 30g, Radix Notoginseng 3g (taking after mixing it with water)
2. Rhizoma Chuanxiong 20g, Radix Et Caulis Acanthopanacis Senticosi 30g, Radix Notoginseng 3g (taking after mixing it with water)
By Rhizoma Chuanxiong and Radix Et Caulis Acanthopanacis Senticosi mixing immersion 40 minutes, intense fire boils rear slow fire boiling 20 minutes, pours Radix Notoginseng powder and takes orally, potion on the one, 21 days courses for the treatment of.
(4) efficacy evaluation:
After terminating the course for the treatment of, according to the improvement situation of patient clinical symptom, divide effectively, effective and invalid.
1. effective: chief complaint improves, positive sign disappears
2. effective: chief complaint improves, and sign still exists; Or symptom is improved not obvious, positive sign disappears
3. invalid: symptom and sign is all without improvement
Result of study:
Meet inclusive criteria carry out altogether 19 example, come off 7 example, other cases the results are shown in Table 7.
Table 7 clinical case result of study
Claims (13)
1. treat a pharmaceutical composition for apoplexy, it is characterized in that described pharmaceutical composition is prepared from by the crude drug of following weight proportion: Rhizoma Chuanxiong 5-40 weight portion, Radix Et Caulis Acanthopanacis Senticosi 9-40 weight portion, Radix Notoginseng 2-15 weight portion.
2. the pharmaceutical composition for the treatment of apoplexy according to claim 1, is characterized in that described pharmaceutical composition is prepared from by the crude drug of following weight proportion: Rhizoma Chuanxiong 13-30 weight portion, Radix Et Caulis Acanthopanacis Senticosi 27-35 weight portion, Radix Notoginseng 3-9 weight portion.
3. the pharmaceutical composition for the treatment of apoplexy according to claim 2, is characterized in that being prepared from by the crude drug of following weight proportion in described pharmaceutical composition: Rhizoma Chuanxiong 15-20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30-35 weight portion, Radix Notoginseng 3-4 weight portion.
4. the pharmaceutical composition for the treatment of apoplexy according to claim 3, is characterized in that described pharmaceutical composition is prepared from by the crude drug of following weight proportion: Rhizoma Chuanxiong 15 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion.
5. the pharmaceutical composition for the treatment of apoplexy according to claim 3, is characterized in that described pharmaceutical composition is prepared from by the crude drug of following weight proportion: Rhizoma Chuanxiong 20 weight portion, Radix Et Caulis Acanthopanacis Senticosi 30 weight portion, Radix Notoginseng 3 weight portion.
6. the pharmaceutical composition of the treatment apoplexy according to any one of claim 1-5, to is characterized in that in described pharmaceutical composition that Rhizoma Chuanxiong is replaced one of in Ligusticum slnense, western rhizome of chuanxiong, golden rhizome of chuanxiong or eastern rhizome of chuanxiong.
7. the pharmaceutical composition of the treatment apoplexy according to any one of claim 1-5, is characterized in that in described pharmaceutical composition, Radix Et Caulis Acanthopanacis Senticosi is replaced by Cortex Acanthopancis.
8. the pharmaceutical composition of the treatment apoplexy according to any one of claim 1-5, is characterized in that in described pharmaceutical composition, Radix Notoginseng is replaced by Folium Notoginseng, flower of Radix Notoginseng or Pollen Typhae.
9. the pharmaceutical composition of the treatment apoplexy according to any one of claim 1-8, is characterized in that described apoplexy is cerebral infarction.
10. the pharmaceutical composition of the treatment apoplexy according to any one of claim 9, is characterized in that described apoplexy is cerebral infarction.
The pharmaceutical composition of 11. treatment apoplexy according to any one of claim 1-8, the dosage form that pharmaceutical composition described in it is characterized in that makes preparation is injection, oral liquid, syrup, tablet, pill, capsule, suppository, powder, Emulsion, suspension or granule.
The pharmaceutical composition of 12. treatment apoplexy according to any one of claim 1-8, after it is characterized in that the preparation method of described pharmaceutical composition comprises the steps: that Rhizoma Chuanxiong and Radix Et Caulis Acanthopanacis Senticosi mixing decoct, Radix Notoginseng powder is added, dry pharmaceutical composition after stirring and evenly mixing in filtrate.
The pharmaceutical composition of 13. treatment apoplexy according to any one of claim 1-8, is characterized in that described apoplexy is stroke at convalescence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210163730.4A CN103417591B (en) | 2012-05-24 | 2012-05-24 | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210163730.4A CN103417591B (en) | 2012-05-24 | 2012-05-24 | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103417591A CN103417591A (en) | 2013-12-04 |
| CN103417591B true CN103417591B (en) | 2016-02-24 |
Family
ID=49643333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210163730.4A Active CN103417591B (en) | 2012-05-24 | 2012-05-24 | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103417591B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887791B (en) * | 2015-07-02 | 2017-12-01 | 湖南文理学院 | A kind of herbal composite and its application method of the bleeding of swamp eel resisting stress |
| CN113577119A (en) * | 2021-07-21 | 2021-11-02 | 右江民族医学院附属医院 | Action mechanism of pseudo-ginseng on cerebral arterial thrombosis and application of action mechanism |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357195A (en) * | 2011-11-04 | 2012-02-22 | 成都中医药大学 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
-
2012
- 2012-05-24 CN CN201210163730.4A patent/CN103417591B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357195A (en) * | 2011-11-04 | 2012-02-22 | 成都中医药大学 | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103417591A (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103638501B (en) | Medicament for treating biliary ascariasis and preparation method of medicament | |
| CN104107299A (en) | Traditional Chinese medicine mixture for treating dysmenorrhoea | |
| CN104474471A (en) | Traditional Chinese medicine composition for treating thyroid | |
| CN104173773A (en) | Preparation with functions of treating migraine, dispelling wind and promoting blood circulation and preparation methods | |
| CN104173517B (en) | The Chinese medicine preparation for the treatment of primary trigeminal neuralgia and preparation method | |
| CN103417591B (en) | A kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof | |
| CN104623376B (en) | Be used for the treatment of prosopalgic medicine | |
| CN104324330A (en) | Traditional Chinese medicine composition for treating blood stasis accumulation type hysteromyoma and preparation method of the traditional Chinese medicine composition | |
| CN103920058A (en) | Traditional Chinese medicine preparation for treating headache and preparation method thereof | |
| CN106039225A (en) | Traditional Chinese medicine preparation for treating acute lumbar muscle sprain | |
| CN105749167A (en) | Traditional Chinese medicine composition for treating amenorrhea | |
| CN102145063B (en) | Traditional Chinese medicine for treating thrombocytopenic purpura | |
| CN105663408A (en) | Decoction medicine for treating abnormal menstruation and insufficient menstrual blood volume as well as preparation method thereof | |
| CN101637558B (en) | Medicament for treating thrombocytolytic purpura | |
| CN104435560A (en) | Traditional Chinese medicine composition for relieving wound pain after wear-off of anesthetic and preparation method of traditional Chinese medicine composition | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN102114150A (en) | Chinese medicine oral decoction for treating endometriosis | |
| CN103705629B (en) | A kind of Chinese medicine composition for the treatment of pruritus | |
| CN107375636B (en) | Traditional Chinese medicine for treating impotence due to kidney deficiency and blood stasis and preparation method thereof | |
| CN104027746B (en) | A kind of spray quickly alleviating postoperative pain and preparation method | |
| CN104666819A (en) | Chinese medicine bath with effects of clearing liver-heat and regulating menstruation | |
| CN104826068A (en) | Medicine for expelling wind and eliminating dampness and preparation method of medicine | |
| CN105477098A (en) | Traditional Chinese medicine composition for recovery from cerebral thrombosis | |
| CN104645109B (en) | A kind of Chinese medicine preparation for treating liver purple plague purpura disease and preparation method thereof | |
| CN104225342A (en) | Chinese herbal preparation for treating nephritis edema and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |